Pieris Pharmaceuticals Inc. and Seattle Genetics Inc. have teamed up to develop bispecific immuno-oncology therapies for solid and blood cancers using both firms' core technologies, Anticalins and antibody-drug conjugates.
The idea is to develop novel antibody-anticalin fusion proteins using the core technologies of both companies: Pieris' proprietary suite of...